AAC Holdings, Inc. provides inpatient and outpatient substance use treatment services for individuals with drug addiction, alcohol addiction, and co-occurring mental/behavioral health issues in the United States. Its therapy services include motivational interviewing, cognitive behavioral therapy, rational emotive behavior therapy, dialectical behavioral therapy, solution-focused therapy, eye movement desensitization and reprocessing, and systematic family intervention. As of June 30, 2018, the company operated 11 inpatient substance abuse treatment facilities, focused on delivering clinical care and treatment solutions across 1,112 inpatient beds, including 732 licensed detoxification beds, 26 standalone outpatient centers, and 5 sober living facilities across 409 beds for a total of 1,521 combined inpatient and sober living beds. It also offers Internet marketing services to families and individuals struggling with addiction and seeking treatment options through online directories of treatment providers, treatment provider reviews, forums, and professional communities; and online marketing solutions to other treatment providers, such as facility profiles, audience targeting, lead generation, and tools for digital reputation management. In addition, the company performs drug testing and diagnostic laboratory services; and provides physician services to its clients. AAC Holdings, Inc. was founded in 2014 and is headquartered in Brentwood, Tennessee.
Industry, Sector and Symbol
Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone615-732-1231
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$317.64 million
Profitability
Miscellaneous
Employees2,100
OptionableOptionable
AAC (NYSE:AAC) Frequently Asked Questions
What is AAC's stock symbol?
AAC trades on the New York Stock Exchange (NYSE) under the ticker symbol "AAC."
How were AAC's earnings last quarter?
AAC Holdings Inc (NYSE:AAC) posted its quarterly earnings results on Wednesday, May, 2nd. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.12 by $0.01. The firm earned $78.50 million during the quarter, compared to analysts' expectations of $75.92 million. AAC had a positive return on equity of 4.21% and a negative net margin of 10.20%. The company's revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.12 earnings per share. View AAC's Earnings History.
When is AAC's next earnings date?
What price target have analysts set for AAC?
2 Wall Street analysts have issued 1-year price objectives for AAC's shares. Their predictions range from $4.00 to $12.00. On average, they anticipate AAC's stock price to reach $8.00 in the next year. This suggests a possible upside of 169.4% from the stock's current price. View Analyst Price Targets for AAC.
What is the consensus analysts' recommendation for AAC?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AAC in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AAC.
What are Wall Street analysts saying about AAC stock?
Here are some recent quotes from research analysts about AAC stock:
- 1. According to Zacks Investment Research, "AAC Holdings, Inc. is a provider of inpatient substance abuse treatment services for individuals with drug and alcohol addiction. It provides detoxification, residential treatment, partial hospitalization, and intensive outpatient care services. AAC Holdings, Inc. is headquartered in Brentwood, Tennessee. " (1/23/2019)
- 2. Cantor Fitzgerald analysts commented, "1Q18 results were ahead of consensus on both the top and bottom lines, although consensus is comprised of only three estimates. Results were boosted by the AdCare acquisition (closed March 1), but we expect more earnings impact from AdCare in 2Q18 and beyond." (5/2/2018)
Has AAC been receiving favorable news coverage?
Press coverage about AAC stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AAC earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of AAC's key competitors?
Some companies that are related to AAC include Evelo Biosciences (EVLO), Iradimed (IRMD), Adamas Pharmaceuticals (ADMS), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Vapotherm (VAPO), STARPHARMA HOLD/S (SPHRY), BIOFRONTERA AG/ADR (BFRA), Minerva Neurosciences (NERV), Depomed (ASRT), Apyx Medical (APYX), Axsome Therapeutics (AXSM), Geron (GERN), Enochian Biosciences (ENOB) and Clover (CLV).
Who are AAC's key executives?
AAC's management team includes the folowing people:
- Mr. Michael T. Cartwright, Chairman & CEO (Age 51)
- Dr. Thomas W. Doub, Chief Compliance Officer & Chief Clinical Officer (Age 50)
- Mr. Michael Nanko Ph.D., Pres & COO (Age 63)
- Mr. Andrew W. McWilliams, CFO & Chief Accounting Officer (Age 47)
- Mr. Michael J. Stetar, Chief Technology Officer
Who are AAC's major shareholders?
AAC's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Royce & Associates LP (6.27%), BlackRock Inc. (3.26%), Mondrian Investment Partners LTD (2.57%), Bank of America Corp DE (1.37%), Empirical Capital Management LLC (1.17%) and Bank of New York Mellon Corp (0.71%). Company insiders that own AAC stock include Darrell S Freeman, David C Kloeppel, Jerrod N Menz, Michael J Blackburn, Michael Nanko, Michael T Cartwright and W Larry Cash. View Institutional Ownership Trends for AAC.
Which major investors are selling AAC stock?
AAC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Barclays PLC. Company insiders that have sold AAC company stock in the last year include David C Kloeppel, Michael J Blackburn and Michael T Cartwright. View Insider Buying and Selling for AAC.
Which major investors are buying AAC stock?
AAC stock was bought by a variety of institutional investors in the last quarter, including Royce & Associates LP, Empirical Capital Management LLC, Assenagon Asset Management S.A., Mondrian Investment Partners LTD, Bank of New York Mellon Corp, Two Sigma Investments LP, BlackRock Inc. and Geode Capital Management LLC. Company insiders that have bought AAC stock in the last two years include Darrell S Freeman, Michael Nanko and W Larry Cash. View Insider Buying and Selling for AAC.
How do I buy shares of AAC?
Shares of AAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AAC's stock price today?
One share of AAC stock can currently be purchased for approximately $2.97.
How big of a company is AAC?
AAC has a market capitalization of $73.07 million and generates $317.64 million in revenue each year. The company earns $-20,570,000.00 in net income (profit) each year or $0.60 on an earnings per share basis. AAC employs 2,100 workers across the globe.
What is AAC's official website?
How can I contact AAC?
AAC's mailing address is 200 POWELL PLACE, BRENTWOOD TN, 37027. The company can be reached via phone at 615-732-1231 or via email at [email protected]
MarketBeat Community Rating for AAC (NYSE AAC)
MarketBeat's community ratings are surveys of what our community members think about AAC and other stocks. Vote "Outperform" if you believe AAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
